48 related articles for article (PubMed ID: 1054622)
1. N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin.
Israel M; Modest EJ; Frei E
Cancer Res; 1975 May; 35(5):1365-8. PubMed ID: 1054622
[TBL] [Abstract][Full Text] [Related]
2. DNA-binding studies of valrubicin as a chemotherapy drug using spectroscopy and electrochemical techniques.
Hajian R; Hossaini P; Mehrayin Z; Woi PM; Shams N
J Pharm Anal; 2017 Jun; 7(3):176-180. PubMed ID: 29404035
[TBL] [Abstract][Full Text] [Related]
3. Fabrication of an electrochemical sensor for determination of doxorubicin in human plasma and its interaction with DNA.
Hajian R; Tayebi Z; Shams N
J Pharm Anal; 2017 Feb; 7(1):27-33. PubMed ID: 29404015
[TBL] [Abstract][Full Text] [Related]
4. Photophysical characterization of anticancer drug valrubicin in rHDL nanoparticles and its use as an imaging agent.
Shah S; Chib R; Raut S; Bermudez J; Sabnis N; Duggal D; Kimball JD; Lacko AG; Gryczynski Z; Gryczynski I
J Photochem Photobiol B; 2016 Feb; 155():60-5. PubMed ID: 26735001
[TBL] [Abstract][Full Text] [Related]
5. Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles.
Sabnis N; Nair M; Israel M; McConathy WJ; Lacko AG
Int J Nanomedicine; 2012; 7():975-83. PubMed ID: 22393294
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and DNA-binding affinity studies of glycosylated intercalators designed as functional mimics of the anthracycline antibiotics.
Shi W; Coleman RS; Lowary TL
Org Biomol Chem; 2009 Sep; 7(18):3709-22. PubMed ID: 19707675
[TBL] [Abstract][Full Text] [Related]
7. Pivotal role of dihydrofolate reductase knockdown in the anticancer activity of 2-hydroxyoleic acid.
Lladó V; Terés S; Higuera M; Alvarez R; Noguera-Salva MA; Halver JE; Escribá PV; Busquets X
Proc Natl Acad Sci U S A; 2009 Aug; 106(33):13754-8. PubMed ID: 19666584
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group.
Ignatoff JM; Chen YH; Greenberg RE; Pow-Sang JM; Messing EM; Wilding G
Urol Oncol; 2009; 27(5):496-501. PubMed ID: 18639470
[TBL] [Abstract][Full Text] [Related]
9. Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.
Nagy A; Plonowski A; Schally AV
Proc Natl Acad Sci U S A; 2000 Jan; 97(2):829-34. PubMed ID: 10639165
[TBL] [Abstract][Full Text] [Related]
10. Valrubicin.
Onrust SV; Lamb HM
Drugs Aging; 1999 Jul; 15(1):69-75; discussion 76. PubMed ID: 10459733
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.
Nagy A; Schally AV; Armatis P; Szepeshazi K; Halmos G; Kovacs M; Zarandi M; Groot K; Miyazaki M; Jungwirth A; Horvath J
Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7269-73. PubMed ID: 8692981
[TBL] [Abstract][Full Text] [Related]
12. Immunotargeting of liposomes containing lipophilic antitumor prodrugs.
Mori A; Kennel SJ; Huang L
Pharm Res; 1993 Apr; 10(4):507-14. PubMed ID: 8483832
[TBL] [Abstract][Full Text] [Related]
13. Disruption of cellular signaling pathways by daunomycin through destabilization of nonlamellar membrane structures.
Escribá PV; Sastre M; García-Sevilla JA
Proc Natl Acad Sci U S A; 1995 Aug; 92(16):7595-9. PubMed ID: 7638236
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic studies with radiolabeled N-trifluoroacetyladriamycin-14-valerate (AD 32). Comparison of total anthracycline fluorescence and radioactivity in mouse serum and urine.
Israel M; Karkowsky AM; Pegg WJ
Cancer Chemother Pharmacol; 1980; 4(2):79-82. PubMed ID: 7389059
[TBL] [Abstract][Full Text] [Related]
15. Cancer chemotherapy: new developments and changing concepts.
Carter SK
Drugs; 1980 Nov; 20(5):375-97. PubMed ID: 7002528
[No Abstract] [Full Text] [Related]
16. Anthracycline cardiomyopathy.
Kobrinsky NL; Ramsay NK; Krivit W
Pediatr Cardiol; 1982; 3(3):265-72. PubMed ID: 6961377
[TBL] [Abstract][Full Text] [Related]
17. Distribution of radioactivity and anthracycline-fluorescence in tissues of mice one hour after [14C]-labeled AD 32 administration. Evidence for tissue aglycone formation.
Israel M; Karkowsky AM; Khetarpal VK
Cancer Chemother Pharmacol; 1981; 6(1):25-30. PubMed ID: 6944160
[TBL] [Abstract][Full Text] [Related]
18. Radioactive species in rat urines and tissues after [14C] AD 32 administration.
Zini G; Vicario GP; Lazzati M; Arcamone F
Cancer Chemother Pharmacol; 1984; 12(3):154-6. PubMed ID: 6705133
[TBL] [Abstract][Full Text] [Related]
19. The mechanism of action of quinone antibiotics.
Lown JW
Mol Cell Biochem; 1983; 55(1):17-40. PubMed ID: 6353197
[TBL] [Abstract][Full Text] [Related]
20. Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines.
Niell HB; Hunter RF; Herrod HG; Israel M
Cancer Chemother Pharmacol; 1987; 19(1):47-52. PubMed ID: 3815726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
